Herceptin plus taxol highly effective in low-risk breast cancer
The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium. "This is great news for patients and their physicians," said Kathy Albain, MD, of Loyola University Medical Center, who is one of the co-authors of the national multicenter study. "This study identifies a new treatment option for this population of patients that is highly effective and has minimal side effects." First author is Sara Tolaney, MD, of the Dana-Farber Cancer Institute…